The importance difference between this trial and the Chinese's trial is that all 12 patients were on a ventilator!!!! Can't wait to see more detail whether these patients were conscious or their conditions prior to REMESTEMCEL-L treatment.
Note with the recent published data of 2634 patients, "373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. Mortality for those requiring mechanical ventilation was 88.1%."
https://jamanetwork.com/journals/jama/fullarticle/2765184
There was 282 deaths among 320 patients on ventilator (88.1% of 320p). This means that another 271 patients (49%) died without a ventilator. I wonder if our Phase II/III trials will include those whom are very sick, but was not intubated? The design of the trial will dictate how many patients can be treated with MSCs. I am thinking of many poorer countries that do not have many ventilators/ICU/Hospital specialists/Drugs to treat Covid-19 patients.
We should be proud!!! Our investment saves lives
- Forums
- ASX - By Stock
- MSB
- Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-65
-
-
- There are more pages in this discussion • 783 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
94.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.073B |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 974 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
90.5¢ | 13354 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 546 | 0.985 |
4 | 645 | 0.965 |
1 | 1005 | 0.950 |
2 | 1063 | 0.945 |
5 | 23592 | 0.940 |
Price($) | Vol. | No. |
---|---|---|
0.915 | 4 | 1 |
0.930 | 790 | 1 |
0.935 | 10000 | 1 |
0.940 | 15642 | 6 |
0.945 | 20000 | 1 |
Last trade - 09.52am 03/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, CEO
James Graham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online